NLRP3 Inhibitor Patent Review for Inflammatory Diseases (2023-Present)

Jannatun N. Namme's review summarizes recent patents on NLRP3 inhibitor development from 2023 onward. It provides an overview of patent applications, priority filings, and the chemical diversity of small molecule inhibitors targeting the NLRP3 inflammasome. The document was last updated in April 2026.

Use Cases

• Analyze trends in patent jurisdictions and territories for NLRP3-targeted therapies.
• Identify new chemical classes and mechanisms of action (MOAs) for NLRP3 inhibitors from patent summaries.
• Review the expansion of patent filings into new therapeutic indications for inflammatory diseases.
• Study the strategic activity and priority filings of different organizations developing NLRP3 inhibitors.

Strengths

• Focuses on recent patent activity from 2023 to the present, providing current analysis.
• Systematically covers diverse chemical scaffolds and mechanisms of action for NLRP3 inhibitors.

Limitations

• The dataset is a single 1.2 MB PDF review document, not a structured database of individual patents.
• No raw data rows or columns are provided, limiting quantitative analysis.
• The scope is defined by the author's review methodology, which may not capture all relevant filings.

Provenance

Source

Jannatun N. Namme, published on figshare.

Collection Method

Patent review and analysis of applications and filings.

Time Range

2023 to present (circa 2026).

Freshness

Last updated on 2026-04-04.

Geography

null